Where the health technology developer amends the development plan of a medicinal product after the submission of the briefing package, it is necessary to set the deadline by which the health technology developer is to submit the relevant updates to the JSC Subgroup so that those updates can be considered in the joint scientific consultation outcome document.
Recital 16, Regulation (EU) 2024/3169
In forcesince 18 Dec 2024